Atossa Genetics is a clinical-stage pharmaceutical company focused on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company's leading program uses its patented intraductal microcatheters that deliver pharmaceuticals through the breast milk ducts. Atossa has initiated a Phase 2 clinical study using its microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer.

Oral endoxifen is the Company's second development program. Endoxifen is an active metabolite of tamoxifen, an FDA approved drug for breast cancer patients to prevent recurrence as well as new breast cancer.

Atossa Genetics is passionate about improving breast health and the overall well-being and health of women and men.

Seattle, US
Size (employees)
18 (est)
Atossa Genetics was founded in 2009 and is headquartered in Seattle, US
Report incorrect company information

Key People/Management at Atossa Genetics

Steven Quay

Steven Quay

Chairman of the Board and Chief Executive Officer
Kyle Guse

Kyle Guse

Chief Financial Officer, General Counsel and Secretary
MSPH Janet Rose Rea

MSPH Janet Rose Rea

Vice President, Regulatory, Quality, Clinical Affairs

Atossa Genetics Office Locations

Atossa Genetics has an office in Seattle
Seattle, US (HQ)
4105 E Madison St
Show all (1)
Report incorrect company information

Atossa Genetics Financials and Metrics

Atossa Genetics Financials

Market capitalization (5-Mar-2018)

6.5 m
Atossa Genetics's current market capitalization is $6.5 m.
Show all financial metrics
Report incorrect company information